Merck (MRK) stock: company licenses SciBrunch's cancer drug SPR2015 in a deal worth up to $2.13 billion, targeting KRAS G12D mutations.
Conversations about cancer research are tough for anyone who has ever been diagnosed, treated, or lost someone to the disease ...
Agenus Inc. has surged >195% YTD, driven by optimism around its BOT/BAL combo therapy for MSS colon cancer. Read more on AGEN ...
4don MSN
Penn helped test a promising mRNA cancer vaccine. Here’s what the trial means for the field.
Denise Fitzsimmons knew that removing the fast-growing lump above her eyebrow in 2024 didn’t eliminate the possibility that ...
FinanceBuzz on MSN
Trump's tariffs could double the price of Ozempic and these other drugs
Trump's 100% pharmaceutical tariffs could double prices for common imported medications. Learn which drugs are affected and ...
Fred Hutch hematologist Marco Mielcarek, MD, PhD, has received a five-year, $3.5 million National Institutes of Health (NIH) U01 collaborative research grant to complete a clinical trial and related ...
- Pfizer PFE-- presented 45 oncology abstracts at ESMO to showcase next-gen drugs like atirmociclib and PF-08634404, ...
A new study, published Sept. 25 in Cancer Discovery, reveals key insights into the biological factors shaping efficacy of off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results